Global Dystrophin 麻豆原创 Research Report 2023

Publication ID:

PB503237617

Publication Date:

March 22, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Dystrophin market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Dystrophin is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Dystrophin is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Dystrophin include Asklepios BioPharmaceutical Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Company Ltd, Editas Medicine Inc, Genethon SA, Nippon Shinyaku Co Ltd, Pfizer Inc, Sarepta Therapeutics Inc and WAVE Life Sciences Ltd, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Dystrophin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dystrophin.
The Dystrophin market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Dystrophin market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dystrophin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Asklepios BioPharmaceutical Inc
BioMarin Pharmaceutical Inc
Daiichi Sankyo Company Ltd
Editas Medicine Inc
Genethon SA
Nippon Shinyaku Co Ltd
Pfizer Inc
Sarepta Therapeutics Inc
WAVE Life Sciences Ltd
Segment by Type
DS-5141
Biostrophin
BMBD-001
NS-065
Others
Segment by Application
Genetic Disorders
Musculoskeletal Disorders
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Dystrophin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Dystrophin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Dystrophin 麻豆原创 Overview
1.1 Product Overview and Scope of Dystrophin
1.2 Dystrophin Segment by Type
1.2.1 Global Dystrophin 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 DS-5141
1.2.3 Biostrophin
1.2.4 BMBD-001
1.2.5 NS-065
1.2.6 Others
1.3 Dystrophin Segment by Application
1.3.1 Global Dystrophin 麻豆原创 Value by Application: (2023-2029)
1.3.2 Genetic Disorders
1.3.3 Musculoskeletal Disorders
1.3.4 Others
1.4 Global Dystrophin 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Dystrophin Revenue 2018-2029
1.4.2 Global Dystrophin Sales 2018-2029
1.4.3 Global Dystrophin 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Dystrophin 麻豆原创 Competition by Manufacturers
2.1 Global Dystrophin Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Dystrophin Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Dystrophin Average Price by Manufacturers (2018-2023)
2.4 Global Dystrophin Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Dystrophin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dystrophin, Product Type & Application
2.7 Dystrophin 麻豆原创 Competitive Situation and Trends
2.7.1 Dystrophin 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Dystrophin Players 麻豆原创 Share by Revenue
2.7.3 Global Dystrophin 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dystrophin Retrospective 麻豆原创 Scenario by Region
3.1 Global Dystrophin 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Dystrophin Global Dystrophin Sales by Region: 2018-2029
3.2.1 Global Dystrophin Sales by Region: 2018-2023
3.2.2 Global Dystrophin Sales by Region: 2024-2029
3.3 Global Dystrophin Global Dystrophin Revenue by Region: 2018-2029
3.3.1 Global Dystrophin Revenue by Region: 2018-2023
3.3.2 Global Dystrophin Revenue by Region: 2024-2029
3.4 North America Dystrophin 麻豆原创 Facts & Figures by Country
3.4.1 North America Dystrophin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Dystrophin Sales by Country (2018-2029)
3.4.3 North America Dystrophin Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Dystrophin 麻豆原创 Facts & Figures by Country
3.5.1 Europe Dystrophin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Dystrophin Sales by Country (2018-2029)
3.5.3 Europe Dystrophin Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dystrophin 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Dystrophin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Dystrophin Sales by Country (2018-2029)
3.6.3 Asia Pacific Dystrophin Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Dystrophin 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Dystrophin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Dystrophin Sales by Country (2018-2029)
3.7.3 Latin America Dystrophin Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dystrophin 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Dystrophin 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Dystrophin Sales by Country (2018-2029)
3.8.3 Middle East and Africa Dystrophin Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dystrophin Sales by Type (2018-2029)
4.1.1 Global Dystrophin Sales by Type (2018-2023)
4.1.2 Global Dystrophin Sales by Type (2024-2029)
4.1.3 Global Dystrophin Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Dystrophin Revenue by Type (2018-2029)
4.2.1 Global Dystrophin Revenue by Type (2018-2023)
4.2.2 Global Dystrophin Revenue by Type (2024-2029)
4.2.3 Global Dystrophin Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Dystrophin Price by Type (2018-2029)
5 Segment by Application
5.1 Global Dystrophin Sales by Application (2018-2029)
5.1.1 Global Dystrophin Sales by Application (2018-2023)
5.1.2 Global Dystrophin Sales by Application (2024-2029)
5.1.3 Global Dystrophin Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Dystrophin Revenue by Application (2018-2029)
5.2.1 Global Dystrophin Revenue by Application (2018-2023)
5.2.2 Global Dystrophin Revenue by Application (2024-2029)
5.2.3 Global Dystrophin Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Dystrophin Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Asklepios BioPharmaceutical Inc
6.1.1 Asklepios BioPharmaceutical Inc Corporation Information
6.1.2 Asklepios BioPharmaceutical Inc Description and Business Overview
6.1.3 Asklepios BioPharmaceutical Inc Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Asklepios BioPharmaceutical Inc Dystrophin Product Portfolio
6.1.5 Asklepios BioPharmaceutical Inc Recent Developments/Updates
6.2 BioMarin Pharmaceutical Inc
6.2.1 BioMarin Pharmaceutical Inc Corporation Information
6.2.2 BioMarin Pharmaceutical Inc Description and Business Overview
6.2.3 BioMarin Pharmaceutical Inc Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.2.4 BioMarin Pharmaceutical Inc Dystrophin Product Portfolio
6.2.5 BioMarin Pharmaceutical Inc Recent Developments/Updates
6.3 Daiichi Sankyo Company Ltd
6.3.1 Daiichi Sankyo Company Ltd Corporation Information
6.3.2 Daiichi Sankyo Company Ltd Description and Business Overview
6.3.3 Daiichi Sankyo Company Ltd Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Daiichi Sankyo Company Ltd Dystrophin Product Portfolio
6.3.5 Daiichi Sankyo Company Ltd Recent Developments/Updates
6.4 Editas Medicine Inc
6.4.1 Editas Medicine Inc Corporation Information
6.4.2 Editas Medicine Inc Description and Business Overview
6.4.3 Editas Medicine Inc Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Editas Medicine Inc Dystrophin Product Portfolio
6.4.5 Editas Medicine Inc Recent Developments/Updates
6.5 Genethon SA
6.5.1 Genethon SA Corporation Information
6.5.2 Genethon SA Description and Business Overview
6.5.3 Genethon SA Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Genethon SA Dystrophin Product Portfolio
6.5.5 Genethon SA Recent Developments/Updates
6.6 Nippon Shinyaku Co Ltd
6.6.1 Nippon Shinyaku Co Ltd Corporation Information
6.6.2 Nippon Shinyaku Co Ltd Description and Business Overview
6.6.3 Nippon Shinyaku Co Ltd Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Nippon Shinyaku Co Ltd Dystrophin Product Portfolio
6.6.5 Nippon Shinyaku Co Ltd Recent Developments/Updates
6.7 Pfizer Inc
6.6.1 Pfizer Inc Corporation Information
6.6.2 Pfizer Inc Description and Business Overview
6.6.3 Pfizer Inc Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Inc Dystrophin Product Portfolio
6.7.5 Pfizer Inc Recent Developments/Updates
6.8 Sarepta Therapeutics Inc
6.8.1 Sarepta Therapeutics Inc Corporation Information
6.8.2 Sarepta Therapeutics Inc Description and Business Overview
6.8.3 Sarepta Therapeutics Inc Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Sarepta Therapeutics Inc Dystrophin Product Portfolio
6.8.5 Sarepta Therapeutics Inc Recent Developments/Updates
6.9 WAVE Life Sciences Ltd
6.9.1 WAVE Life Sciences Ltd Corporation Information
6.9.2 WAVE Life Sciences Ltd Description and Business Overview
6.9.3 WAVE Life Sciences Ltd Dystrophin Sales, Revenue and Gross Margin (2018-2023)
6.9.4 WAVE Life Sciences Ltd Dystrophin Product Portfolio
6.9.5 WAVE Life Sciences Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dystrophin Industry Chain Analysis
7.2 Dystrophin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dystrophin Production Mode & Process
7.4 Dystrophin Sales and 麻豆原创ing
7.4.1 Dystrophin Sales Channels
7.4.2 Dystrophin Distributors
7.5 Dystrophin Customers
8 Dystrophin 麻豆原创 Dynamics
8.1 Dystrophin Industry Trends
8.2 Dystrophin 麻豆原创 Drivers
8.3 Dystrophin 麻豆原创 Challenges
8.4 Dystrophin 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Asklepios BioPharmaceutical Inc
BioMarin Pharmaceutical Inc
Daiichi Sankyo Company Ltd
Editas Medicine Inc
Genethon SA
Nippon Shinyaku Co Ltd
Pfizer Inc
Sarepta Therapeutics Inc
WAVE Life Sciences Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.